Navigation Links
Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients

This press release is available in Spanish.

Barcelona, Spain: In patients with early breast cancer, giving radiotherapy to the lymph nodes located behind the breast bone and above the collar bone is well-tolerated, after mastectomy or breast conserving surgery, a radiation oncologist will tell delegates at the seventh European Breast Cancer Conference (EBCC7) today (Saturday 27 March). Women at a high risk of developing breast cancer will probably benefit from additional lymph node radiotherapy, Dr Philip Poortmans, from the Dr. Bernard Verbeeten Instituut, Tilburg, The Netherlands, and a member of the EORTC* Radiation Oncology Group, will say.

Initial findings from the 4,004-patient multi-centre study carried out by the EORTC radiotherapy and breast cancer groups (46 institutions from 13 countries) show that there is no evidence of increased toxicity to the heart at three years follow-up in patients who received additional lymph node radiotherapy.

Patients will be followed-up for many years to see whether specific lymph-node radiotherapy could lead to long-term damage of the heart or the lungs, side effects that are associated with breast cancer radiotherapy.

Dr Philip Poortmans, one of the trial co-ordinators, will tell delegates that the longer-term aim of the EORTC study is to see whether giving additional radiotherapy to the lymph nodes located behind the breast bone and above the collar bone (internal mammary and medial supraclavicular [IM-MS] lymph nodes) to patients with early operable breast cancer will improve overall survival.

"The first analysis of the primary endpoint, overall survival at 10 years, was planned to be performed in 2012. However, thanks to the actual survival estimate that is even higher than expected, this might have to be postponed until 2014," Dr Poortmans will say.

"We are hopeful that we will see a survival benefit of at least five percent in patients at the time of the primary analysis," Dr Poortmans will say. "With a median follow-up of over seven years, 558 patients have died, so the estimated 10-year overall survival rate of 79%󈞿% is even above the anticipated range," he added.

The majority of patients (76%) had breast-conserving surgery and the remainder had undergone complete removal of their breast (24%). All patients (99.4%) who had breast-conserving surgery received standard radiotherapy to the breast as well as a boost, and 73% of mastectomy treated patients received chest wall radiotherapy. Following this, patients were randomised to receive IM-MS lymph node radiotherapy or no further lymph node therapy.

Radiotherapy is usually given after breast cancer surgery to destroy any cancer cells that remain in the breast, chest wall, or underarm area, in order to reduce the risk of a local recurrence of cancer in that breast. But there is disagreement amongst cancer experts regarding the management of the internal mammary lymph nodes (lymph nodes located behind the breast bone) in patients with breast cancer. The question of whether specific internal mammary lymph node radiotherapy leads to improved survival in women with early breast cancer is currently being addressed by the EORTC radiotherapy and breast cancer groups.

Dr Poortmans said that the final overall survival data analysis will show if internal mammary lymph node radiotherapy provides local control and improves overall survival in women with early breast cancer. "This is an important issue for radiotherapists and breast cancer patients alike, and we are eagerly awaiting the efficacy results from this trial," he says.


Contact: Kay Roche
ECCO-the European CanCer Organisation

Related biology news :

1. Genome mapping technique speeds process of finding specific genes
2. Gene-based stem cell therapy specifically removes cell receptor that attracts HIV
3. Ben-Gurion University Alzheimers researcher demonstrates specific immune response to vaccine
4. LSUHSC research helps link schizophrenia to specific DNA region
5. Specific genetic cause of fetal alcohol-related developmental disorders found
6. New tool isolates RNA within specific cells
7. Researchers identify specific lung cancer susceptibility gene
8. The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders
9. The quest for specific anti-inflammatory treatment
10. Study reveals specific gene in adolescent men with delinquent peers
11. Researchers seeking to identify Alzheimers risk focus on specific blood biomarker
Post Your Comments:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology: